Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study.
Giuseppe LapadulaLuca MezzadriGiustina Lo CascioLaura AntoliniSergio MalandrinAlice RanzaniSilvia LimontaAnnalisa CavalleroPaolo BonfantiPublished in: Infection (2024)
This study suggests that levels of anti-S antibodies can predict critical or fatal outcomes in COVID-19 pneumonia patients, regardless of vaccination. Whether anti-S Ab could guide risk assessment and vaccination boosting merits further evaluation.
Keyphrases
- coronavirus disease
- sars cov
- risk assessment
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- type diabetes
- heavy metals
- respiratory syndrome coronavirus
- intensive care unit
- human health
- weight loss
- respiratory failure
- insulin resistance
- community acquired pneumonia
- clinical evaluation